X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
4.120
-0.090 (-2.14%)
At close: Apr 28, 2026, 4:00 PM EDT
4.130
+0.010 (0.24%)
After-hours: Apr 28, 2026, 7:32 PM EDT

X4 Pharmaceuticals Stock Forecast

Stock Price Forecast

The 4 analysts with 12-month price forecasts for X4 Pharmaceuticals stock have an average target of 9.00, with a low estimate of 5.00 and a high estimate of 12. The average target predicts an increase of 118.45% from the current stock price of 4.12.

Analyst Consensus: Strong Buy
Target Low Average Median High
Price $5.00 $9.00 $10 $12
Change +21.36% +118.45% +142.72% +191.26%
* Price targets were last updated on Mar 9, 2026.

Analyst Ratings

The average analyst rating for X4 Pharmaceuticals stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Nov '25Dec '25Jan '26Feb '26Mar '26Apr '26
Strong Buy 233344
Buy 111110
Hold 000000
Sell 000000
Strong Sell 000000
Total 344454

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
Guggenheim
Guggenheim
Strong Buy
Initiates
$12
Strong Buy Initiates $12 +191.26% Mar 9, 2026
Stifel
Stifel
Strong Buy
Maintains
$7.5$10
Strong Buy Maintains $7.5$10 +142.72% Dec 5, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Maintains
$3.5$5
Strong Buy Maintains $3.5$5 +21.36% Nov 10, 2025
Stifel
Stifel
Strong Buy
Maintains
$30$9
Strong Buy Maintains $30$9 +118.45% Aug 29, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Maintains
$7$3.5
Strong Buy Maintains $7$3.5 -15.05% Aug 13, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
8.19M
from 35.11M
Decreased by -76.66%
Revenue Next Year
7.34M
from 8.19M
Decreased by -10.37%
EPS This Year
-0.89
from -1.87
EPS Next Year
-0.84
from -0.89
Fiscal Year FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027
Period Ending Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026 Dec 31, 2027
Revenue
---2.56M35.11M8.19M7.34M
Revenue Growth
----1,273.21%-76.66%-10.37%
EPS
-119.59-45.53-17.07-5.59-1.87-0.89-0.84
EPS Growth
-------
Forward PE
-------
No. Analysts -----55
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20262027202820292030
High 11.6M 8.3M
Avg 8.2M 7.3M
Low 6.2M 6.4M

Revenue Growth

Revenue Growth 20262027202820292030
High
-67.1%
1.2%
Avg
-76.7%
-10.4%
Low
-82.4%
-22.3%

EPS Forecast

EPS 20262027202820292030
High -0.74 -0.58
Avg -0.89 -0.84
Low -1.02 -0.95

EPS Growth

EPS Growth 20262027202820292030
High - -
Avg - -
Low - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.